|
Exudative Age-Related Macular Degeneration Part 2 |
 |
 |
 |
|
Written by Carlos Verges, MD, Jorge Cazal, MD, Cosme Lavin, MD.
|
Carlos Verges, MD,Ph.D;
Jorge Cazal, MD;
Cosme Lavin, MD |
Exudative Age-Related Macular Degeneration Part 2
Volume 33, Number # 5, 2005 Series
Carlos Verges, MD,Ph.D;
Jorge Cazal, MD;
Cosme Lavin, MD |
1. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22:143-152.
2. Higgins RD, Sanders RJ, Tan Y, et al. Squalamine Improves Retinal Neovascularization. Invest Ophthalmol Vis Sci 2000;41:1507-1512.
3. Nambu H, Nambu R, Melia M, Campochiaro PA. Combretastatin A-4 Phosphate Suppresses Development and Induces Regression of Choroidal Neovascularization. Invest Ophthalmol Vis Sci 2003;44:3650-3655.
4. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003;9:210-216.
|
